FIELD: medicine.
SUBSTANCE: invention relates to a compound of formula (I') having the properties of an inhibitor of the IKAROS family zinc finger protein 2 (IKZF2), or a pharmaceutically acceptable salt thereof, a pharmaceutical composition based on them for the treatment of a disease or disorder affected by a decrease in IKZF2 protein levels, a method for destroying IKZF2, a method for modulating and reducing IKZF2 protein levels, a method of treatment and their use in the treatment of a disease or disorder affected by modulation of IKZF2 protein levels. In the general formula (I') each of X1 and X2 independently represents H or halogen; Rx is H;
R1 is either
or
The remaining values of the radicals are indicated in the claims.
EFFECT: obtaining an inhibitor of the IKAROS family zinc finger protein 2 (IKZF2), or a pharmaceutically acceptable salt thereof.
30 cl, 14 tbl, 185 ex
| Title | Year | Author | Number |
|---|---|---|---|
| 3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USE THEREOF IN TREATING DISEASES ASSOCIATED WITH ZINC FINGER PROTEIN 2 OF IKAROS (IKZF2) FAMILY | 2019 |
|
RU2815714C2 |
| COMPOSITIONS AND METHODS OF SELECTIVE PROTEIN DEGRADATION | 2018 |
|
RU2811700C2 |
| ANTIBODY AND DRUG CONJUGATES (ADC) AND ANTIBODY AND PRODRUG CONJUGATES (APDC) CONTAINING ENZYMATICALLY CLEAVABLE GROUPS | 2016 |
|
RU2751512C2 |
| FGF21 DERIVATIVES AND USE THEREOF | 2015 |
|
RU2729011C2 |
| CONJUGATE OF TROP-2 ANTIBODY AND EXATECAN ANALOGUE AND MEDICAL USE THEREOF | 2021 |
|
RU2830167C1 |
| COMPOSITION FOR TREATING IGF-1R EXPRESSING CANCER | 2016 |
|
RU2728568C2 |
| ANTIBODY TO B7H3-EXATECAN ANALOGUE CONJUGATE AND ITS USE IN MEDICINE | 2019 |
|
RU2785664C2 |
| N1/N2-LACTAM ACETYL-CoA-CARBOXYLASE INHIBITORS | 2011 |
|
RU2540337C2 |
| CONJUGATES OF BINDER AND ACTIVE SUBSTANCE (ADC) HAVING ENZYMATICALLY CLEAVABLE GROUPS | 2017 |
|
RU2761390C2 |
| ANTIBODY-STING AGONIST CONJUGATES AND USE THEREOF IN IMMUNOTHERAPY | 2020 |
|
RU2826228C2 |
Authors
Dates
2023-06-07—Published
2019-07-08—Filed